首页> 外文期刊>Journal of Medicinal Chemistry >Microtubule-Stabilizing 1,2,4-Triazolo1,5-apyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure-Activity Insights
【24h】

Microtubule-Stabilizing 1,2,4-Triazolo1,5-apyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure-Activity Insights

机译:微管稳定1,2,4-三唑并1,5-a嘧啶作为神经退行性疾病的候选疗法:匹配的分子对分析和计算研究揭示了新的构效见解

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Microtubule (MT)-stabilizing 1,2,4-triazolo1,5-a-pyrimidines (TPDs) hold promise as candidate therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions. However, depending on the choice of substituents around the TPD core, these compounds can elicit markedly different cellular phenotypes that likely arise from the interaction of TPD congeners with either one or two spatially distinct binding sites within tubulin heterodimers (i.e., the seventh site and the vinca site). In the present study, we report the design, synthesis, and evaluation of a series of new TPD congeners, as well as matched molecular pair analyses and computational studies, that further elucidate the structure-activity relationships of MT-active TPDs. These studies led to the identification of novel MT-normalizing TPD candidates that exhibit favorable ADME-PK, including brain penetration and oral bioavailability, as well as brain pharmacodynamic activity.
机译:微管 (MT) 稳定 1,2,4-三唑并[1,5-a]-嘧啶 (TPD) 有望成为阿尔茨海默病 (AD) 和其他神经退行性疾病的候选疗法。然而,根据TPD核心周围取代基的选择,这些化合物可以引发明显不同的细胞表型,这些表型可能是由于TPD同系物与微管蛋白异二聚体内一个或两个空间上不同的结合位点(即第七位点和长春花位点)的相互作用而产生的。在本研究中,我们报道了一系列新型TPD同系物的设计、合成和评估,以及匹配的分子对分析和计算研究,进一步阐明了MT活性TPDs的构效关系。这些研究导致确定了具有良好 ADME-PK 的新型 MT 标准化 TPD 候选物,包括脑渗透和口服生物利用度,以及脑药效学活性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号